Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Curetis Second Generation Implant, Tissue Infection Application Cartridge Conforms to CE-IVD Marking

Curetis Second Generation Implant, Tissue Infection Application Cartridge Conforms to CE-IVD Marking

Sep 07, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Curetis said today that based on a performance evaluation for the newest version of its Unyvero ITI Implant and Tissue Infection Application Cartridge, it has marked the cartridge as conforming with previous CE-IVD Marking. The firms also plans to launch the new generation cartridge internationally in the third quarter of 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

  2. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  3. FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

  4. Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

  5. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.